



APPA 2020 Virtual Conference Resident Poster Presentation

Abstract 20-2-06

Title: Olanzapine Induced Hair Loss – A Case Series

Authors: Darshana S. Pai, MD; Ashish Srivastava, MD; J. Luke Engeriser, MD

Summary: Several psychotropic medications have been implicated in hair loss—most commonly, valproic acid and lithium. The reported dermatological side effects associated with antipsychotic agents are rash, pruritus, photosensitivity, skin pigmentation, fixed drug eruptions, and alopecia (1,2,3). However, the number of studies which report atypical antipsychotic induced alopecia is quite limited to a few case reports. Olanzapine is an atypical antipsychotic and has been widely used in the treatment of psychosis and mood disorders. Although it is generally well tolerated, it has been associated with the adverse effect of metabolic syndrome. We present a case series in which several adult female patients reported hair loss following administration of olanzapine which resolved after cessation or decrease of dosage of the drug.

References:

1. Warnock JK. Psychotropic medications and drug-related alopecia. *Psychosomatics* 1991;32(2):149-52.
2. Mercke Y, Sheng H, Khan T, Lippmann S. Hair loss in psychopharmacology. *Ann Clin Psychiatry* 2000;12(1):35-42.
3. McLean RM, Harrison-Woolrych M. Alopecia associated with quetiapine. *Int Clin Psychopharmacol* 2007;22(2):117-9.